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ABSTRACT  
Primary screening for high-risk human papillomavirus (hrHPV) requires a triage protocol. 
Repeat cytology testing at baseline and after 6-12 months has emerged as a reasonable triage 
approach, but carries the risk of loss to follow-up. Repeat cytology testing may be omitted if 
cytology is supplemented with another, complementary triage test at baseline. In this study, 
the performance of combined triage by cytology and DNA methylation analysis was 
assessed. In hrHPV-positive cervical scrapes (n=250), cytology (threshold: atypical 
squamous cells of undetermined significance (ASCUS)), bi-marker CADM1/MAL 
methylation testing (at different assay thresholds) and combinations of both, were evaluated 
for endpoints cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and grade 3 or 
worse (CIN3+). At a predefined methylation threshold of 70% specificity for CIN3+, 
combined triage revealed a CIN3+ sensitivity of 86.8% (95% CI: 76.1-97.6) compared to 
65.8% (95% CI: 50.7-80.9) for sole cytology triage testing. Corresponding CIN3+ specificity 
was 64.8% (95% CI: 58.1-71.5) for combined triage, and 78.6% (95% CI: 72.8-84.3) for sole 
cytology triage testing. For CIN2+, the sensitivity of combined triage testing was 84.5% 
(95% CI: 75.2-93.8) versus 65.5% (95% CI: 53.3-77.7) for sole cytology triage, with 
corresponding specificities of 69.9% (95% CI: 63.1-76.6) and 83.5% (95% CI: 78.0-89.0), 
respectively. In conclusion, combined triage reached substantially higher CIN2+/3+ 
sensitivities compared to sole cytology at a slight drop in specificity. Therefore, it is an 
attractive triage strategy for colposcopy of hrHPV-positive women with a high reassurance 
for cervical cancer and advanced CIN lesions. 
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INTRODUCTION  
Due to its high sensitivity for high-grade cervical disease (i.e., cervical intraepithelial 
neoplasia grade 2/3, CIN2/3) and cervical cancer, testing for high-risk human papillomavirus 
(hrHPV) DNA is likely to become the primary method for cervical cancer screening in the 
near future (1–4). However, the main drawback of the hrHPV test is its lower specificity for 
CIN2/3 or worse (CIN2/3+) than cytology (5). To compensate for this limitation, different 
triage algorithms have been suggested aiming to reduce the number of hrHPV-positive 
women to be referred for colposcopy, thereby limiting over diagnosis and overtreatment. 
Cytology testing is nowadays considered a logical and feasible triage method. However, 
cytology testing at baseline alone has insufficient negative predictive value for CIN2/3+, and 
thus hrHPV-positive women with a negative baseline cytology test cannot be dismissed from 
further follow-up. Repeat cytology testing at baseline and after 6-12 months has emerged as 
an effective triage approach (6,7), but carries the risk of loss to follow-up. Repeat cytology 
testing may be omitted if cytology is supplemented with another, complementary triage test at 
baseline. One such test, i.e., HPV16/18 genotyping, seems to be useful in certain settings 
(6,7).  
Measurement of DNA methylation of promoter regions of host cell tumor suppressor genes 
has shown promise as molecular triage test (8–10). In our previous study, combined analysis 
of CADM1 (cell adhesion molecule 1) and MAL (T-lymphocyte maturation-associated 
protein) gene promoter methylation by quantitative methylation-specific PCR (qMSP) in 
hrHPV-positive cervical scrapes, revealed an equal sensitivity for CIN3+ as cytology at the 
same specificity (11). Levels of CADM1 and MAL methylation in hrHPV-positive cervical 
scrapes increase proportionally to the degree and the duration of underlying high-grade 
cervical disease and are particularly high in scrapes of women with advanced CIN3 and 
cervical cancer (12). Previous data (11,13) suggest that DNA methylation analysis as triage 
test in hrHPV-positive women tends to be relatively more sensitive for CIN3 lesions and 
cervical cancer, whereas cytology is relatively more sensitive for CIN2 lesions. As such, 
DNA methylation analysis might be an interesting supplementary triage test to detect 
clinically relevant cervical lesions missed by cytology. In this study, we explored the 
performance of combined cytology and bi-marker CADM1/MAL methylation analysis at 
baseline compared to sole cytology testing at baseline, and assessed its potential as alternative 
triage strategy for hrHPV-positive women in cervical cancer screening.  
MATERIALS AND METHODS 
Cervical scrapes of hrHPV-positive women 
Cytology and methylation data for CADM1 and MAL genes of a consecutive series of 250 
hrHPV GP5+/6+-PCR-positive cervical scrapes were used (11). The scrapes were from 
women who participated in population-based screening using the same screening and referral 
algorithm as in the intervention arm of the POBASCAM trial (14). In short, co-testing for 
hrHPV and cytology on the cervical scrapes at baseline was performed. Cytology was 
assessed according to the CISOE-A classification that can be easily converted into either the 
British or the 2001 Bethesda system (15). Borderline or mild dyskaryosis (BMD) corresponds 
to atypical squamous cells of undetermined significance (ASCUS), atypical squamous cells 
that cannot exclude high-grade squamous intraepithelial lesions (ASC-H), or low-grade 
squamous intraepithelial lesions (LSIL). Moderate or worse dyskaryosis (>BMD) 
corresponds to high-grade squamous intraepithelial lesions (HSIL). All women with >BMD 
cytology were directly referred for colposcopy; hrHPV-positive women with BMD cytology 
were advised to repeat cytology and hrHPV testing at 6 and 18 months. These women were 
referred for colposcopy at 6 months, if they had >BDM cytology, or BMD cytology in 
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combination with a positive hrHPV test result. The women were referred at 18 months if they 
had >BMD cytology and/or an hrHPV-positive test result. Women with a positive hrHPV test 
result and normal cytology at baseline were advised to repeat cytology and hrHPV testing at 
6 and 18 months. They were referred at 6 months if they had >BMD cytology, and were 
referred at 18 months if they had >BMD cytology and/or a positive hrHPV test result. 
Methylation data for CADM1 and MAL genes were generated by qMSP analysis as described 
before (11). In short, left-over DNA that was used for HPV testing was treated first with 
sodium bisulphite, and resulting converted DNA was subjected to qMSP for CADM1/MAL 
and ACTB as reference gene. Ct ratios were calculated (using the formula 2[Ct (ACTB)- Ct (target)] x 
100) to quantify the methylation level of the target genes. Samples with a Ct>40 were 
considered negative for methylation of the respective target gene, and samples with a Ct 
value of the ACTB>32 were considered invalid and excluded from analysis because of an 
indication of poor DNA quality or recovery after bisulphite treatment. 
A total of 234 hrHPV-positive scrapes had both valid cytology and qMSP results of the bi-
marker panel CADM1/MAL. These included 38 scrapes of women with a CIN3+ lesion (i.e., 
34 CIN3, 1 adenocarcinoma in situ (ACIS), and 3 squamous cell carcinomas (SCCs)) with a 
median age of 34.5 years (range 25-61), and 20 women with a CIN2 lesion (median age of 
33.5 years; range 24-49). Histology was assessed on colposcopy-guided biopsies that were 
taken according to standard procedures in the Netherlands (www.oncoline.nl) within 36 
months of follow-up. The remaining 176 women had no evidence of CIN2+, further referred 
to as ≤CIN1, within the same follow-up time (including 15 CIN1 and 10 histologically-
confirmed absence of CIN). The median age of this group was 40 years (range 19-62).  
 
Data and statistical analysis  
Specimens were recorded as positive for methylation when either or both markers had a 
qMSP outcome above a predefined threshold. Thresholds have previously been set as Ct 
ratios giving rise to CIN3+ specificity values of >20%, >30%, >40%, >50%, >60%, >70%, 
and >80% (11). Receiver operating characteristic (ROC) curves (for endpoints CIN2+ and 
CIN3+) were constructed for the methylation marker panel combined with cytology (i.e., 
recording positive if either methylation or cytology testing or both were above their 
threshold). The threshold used for cytology positivity was ASCUS (i.e., BMD) (15). The 
ROC curve was compared with the CIN2+ and CIN3+ sensitivities and specificities of 
cytology. The positive predictive values (PPVs), negative predictive values (NPVs) and their 
95% Wald confidence intervals (95% CIs) were calculated for endpoints CIN2+ and CIN3+, 
and referral rates for colposcopy (with 95% CIs) were determined by dividing the number of 
women with a positive triage test result by the number of hrHPV-positive women. For the 
latter analyses, the threshold that was used to score the bi-marker CADM1/MAL methylation 
assay positive comprised the validated Ct ratios that corresponded to a CIN3+ specificity of 
>70% (11). All calculations were performed in Microsoft Excel (2010) and SPSS (version 
20).  
RESULTS  
We determined the performance of combined triage by the bi-marker CADM1/MAL 
methylation assay (using validated thresholds (11)) and cytology (threshold of ASCUS (i.e., 
BMD)) in hrHPV-positive cervical scrapes for detection of CIN2+ and CIN3+, respectively. 
ROC curve analysis revealed that, relative to sole cytology and sole methylation testing, 
combined testing for both parameters yielded higher sensitivities for CIN2+ at specificities 
that were similar to those of sole methylation testing (Figure 1A). Similar findings were 
evident for CIN3+, although difference of ROC curves between the combined triage and 
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methylation analysis alone was less pronounced (Figure 1B). At the threshold for the bi-
marker CADM1/MAL methylation assay that corresponded with >70% CIN3+ specificity in 
our previous study (11), combined cytology and methylation analysis revealed a CIN3+ 
sensitivity of 86.8% (95% CI: 76.1-97.6) compared to 65.8% (95% CI: 50.7-80.9) for sole 
cytology triage testing. Corresponding CIN3+ specificity was 64.8% (95% CI: 58.1-71.5) for 
combined triage, and 78.6% (95% CI: 72.8-84.3) for sole cytology triage test (Table 1). For 
CIN2+, the sensitivity of combined cytology and methylation marker triage testing was 
84.5% (95% CI: 75.2-93.8) vs. 65.5% (95% CI: 53.3-77.7) for sole cytology triage, with 
corresponding specificities of 69.9% (95% CI: 63.1-76.6) and 83.5% (95% CI: 78.0-89.0), 
respectively. The PPV for CIN2+ was 48.0% (95% CI: 38.3-57.7) for combined triage and 
56.7% (95% CI: 44.9-68.6) for sole cytology. For CIN3+ outcome, these figures were 32.4% 
(95% CI: 23.3-41.4) and 37.3% (95% CI: 25.7-48.9; Table 1), respectively. The NPV for 
CIN2+ was 93.2% (95% CI: 88.9-97.5) for combined triage and 88.0% (95% CI: 83.1-92.9) 
for sole cytology. For CIN3+ outcome, these figures were 96.2% (95% CI: 93.0-99.5) and 
92.2% (95% CI: 88.2-96.3; Table 1), respectively. The referral rate for CIN2+ in case of 
combined triage was 43.6% (95% CI: 37.4-50.0), compared to 28.6% (95% CI: 23.3-34.7) for 
sole cytology testing (Table 1). 
 
DISCUSSION  
We explored the value of triage testing of hrHPV-positive women by combined cytology and 
bi-marker CADM1/MAL methylation analysis in a population-based cervical screening 
population, and demonstrated a complementary effect of these triage tools. Combined triage 
reached substantially higher CIN2+/3+ sensitivities compared to sole cytology at a slight 
drop in specificity. Therefore, it is an attractive candidate triage tool for hrHPV-positive 
women.  
Since increased methylation of CADM1 and MAL was found to parallel increasing severity 
and duration of cervical disease (12), it is likely that additive methylation analysis 
particularly provides an extra safety net in terms of not missing women with advanced CIN 
disease or cervical cancer (10). Studies indeed have shown that methylation assays applied to 
cervical scrapes or self-collected specimens detected all cervical carcinomas (11,16,17). In 
addition, a higher detection rate of CIN3 among women of older age, which may reflect a 
higher duration of lesion existence, has been reported for methylation analysis (16,17). The 
preference of methylation analysis for more advanced lesions is further supported by the fact 
that, relative to sole cytology, the gain in sensitivity of the combined analysis is higher for 
CIN3+ than for CIN2+ (Table 1). Conversely, relative to methylation testing solely, 
combined triage testing tends to a higher increase in sensitivity for CIN2+ and less for CIN3+ 
at a similar specificity (Figures 1A and 1B). This indicates that, in addition to overlap, both 
assays in part detect different lesions, with cytology having a better sensitivity for CIN2 
lesions and methylation analysis for CIN3+ lesions. As such, combined cytology and 
methylation marker testing by the CADM1/MAL panel is an attractive triage strategy for 
colposcopy of hrHPV-positive women, with a combined negative test providing a high 
reassurance for absence of cervical cancer and advanced CIN lesions. On the other hand, still 
a small number of CIN2+/3+ lesions is not detected by combined cytology and methylation 
triage of hHPV-positive women. Possible reasons for non-detection of these cases by both 
cytology and methylation analysis could be incorrect sampling of the cervical scrapes, or the 
presence of early onset CIN2/3 lesions with a low cancer progression risk that might have 
limited numbers of abnormal cells and/or low methylation levels in their corresponding 
scrape. The addition of other potential molecular markers, or identification of even better 
differentially methylated genes, to be identified by genome-wide methods, might improve the 
diagnostic accuracy of molecular triage testing in the future. Furthermore, it should be noted 
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that the complementary effect of methylation marker analysis to cytology was observed in a 
setting where quality of cytology is high (18). Accordingly, molecular triage by methylation 
markers might even be more advantageous in settings with less adequate cytology 
infrastructure, or may even be a promising alternative to cytology (10). Methylation analysis 
can be performed on the same DNA isolate as used for HPV DNA testing, and has an 
objective read-out. Multiplex PCR technologies furthermore allow analyzing multiple 
methylation targets and an internal control in a multiplex reaction using a single aliquot of 
DNA, thereby saving material, time and costs, and improving throughput and quality control 
(19). A prototype version of a commercial, standardized multiplex qMSP test including 
CADM1 and MAL targets, has recently been developed (PreCursor-M assay, Self-screen B.V, 
Amsterdam, The Netherlands).  
In conclusion, combined cytology and methylation marker testing by the CADM1/MAL panel, 
is an attractive triage strategy for colposcopy of hrHPV-positive women with a high 
reassurance for cervical cancer and advanced CIN lesions. 
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TABLE 
Table 1. Sensitivity, specificity, PPV and NPV for endpoints CIN2+ and CIN3+, and 
referral rates for colposcopy for different triage strategies 
Triage marker Sensitivity (%)     (95% CI) 
Specificity (%)         
(95% CI) 
PPV (%)                     
(95% CI) 
NPV (%)              
(95% CI) 
Referral Rate (%)          
(95% CI) 
CIN2+ (A)           
cytology 65.5 (53.3-77.7) 83.5 (78.0-89.0) 56.7 (44.9-68.6) 88.0 (83.1-92.9) 28.6 (23.3-34.7) 
CADM1/MAL (spec ≥70%) 62.1 (49.6-74.6) 78.4 (72.3-84.5) 48.6 (37.3-60.0) 86.3 (80.9-91.6) 31.6 (26.0-37.8) 
cytology and/or CADM1/MAL ( spec ≥70%) 84.5 (75.2-93.8) 69.9 (63.1-76.6) 48.0 (38.3-57.7) 93.2 (88.9-97.5) 43.6 (37.4-50.0) 
CIN3+ (B)      
cytology 65.8 (50.7-80.9) 78.6 (72.8-84.3) 37.3 (25.7-48.9) 92.2 (88.2-96.3) 28.6 (23.3-34.7) 
CADM1/MAL (spec ≥70%) 68.4 (53.6-83.2) 75.5 (69.5-81.5) 35.1 (24.3-46.0) 92.5 (88.4-96.6) 31.6 (26.0-37.8) 
cytology and/or CADM1/MAL ( spec ≥70%) 86.8 (76.1-97.6) 64.8 (58.1-71.5) 32.4 (23.3-41.4) 96.2 (93.0-99.5) 43.6 (37.4-50.0) 
 
Abbreviations: PPV= positive predictive value, NPV= negative predictive value, CI= confidence interval 
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FIGURE 
Figure 1. Colposcopy triage by combined cytology and bi-maker CADM1/MAL 
methylation analysis in cervical scrapes of 234 hrHPV-positive women. 
 
Shown are the ROC curves for CIN2+ (A) and CIN3+ (B) of combined cytology and bi-
maker CADM1/MAL methylation analysis (black line, dots) and sole bi-marker CADM1/MAL 
methylation analysis (grey line, squares). In addition, the point estimate of cytology is 
projected (triangle). 
